Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human ErbB-2/HER2 Protein, His Tag, 1mg  

Recombinant human ErbB-2/HER2 Protein, His Tag, 1mg

Recombinant Human HER2 /ErbB2 /CD340 Protein (rhHER2) Thr23-Thr652 produced in human HEK293 cells, His Tag

Synonym
recombinant, human, protein ERBB2, CD340, HER-2, HER-2/neu, HER2, MLN19, NEU, NGL, TKR1, ERBB-2, Epidermal-growth-factor-Receptor-2

More details

HE2-H5225-1K

Availability: within 7 days

2 180,00 €

Background
Human Epidermal growth factor Receptor 2 (HER2),also called ERBB2, HER-2,HER-2/neu, NEU, NGL,TKR1 and c-erb B2,and is a protein giving higher aggressiveness in breast cancers. It is a member of the ErbB protein family, more commonly known as the epidermal growth factor receptor family. HER2 is a cell membrane surface-bound receptor tyrosine kinase and is normally involved in the signal transduction pathways leading to cell growth and differentiation.[1] HER2 is thought to be an orphan receptor, with none of the EGF family of ligands able to activate it. Approximately 30% of breast cancers have an amplification of the HER2 gene or overexpression of its protein product. Overexpression of this receptor in breast cancer is associated with increased disease recurrence and worse prognosis. HER2 appears to play roles in development, cancer,communication at the neuromuscular junction andregulation of cell growth and differentiation [2-6].

Source
Recombinant Human HER2 /ErbB2 /CD340 Protein (rhHER2) Thr23-Thr652 (Accession # AAA75493) was produced in human 293 cells (HEK293).

Bioactivity
Measured by its binding ability in a functional ELISA. Immobilized Human Her2, His Tag (Catalog # HE2-H5225) at 0.05 μg/mL (100 μL/well) can bind Trastuzumab with a linear range of 0.2-3 ng/mL.

Molecular Characterization
rhHER2 contains C-terminal polyhistidine tag and has a calculated MW of 72.4 kDa. The predicted N-terminus is Thr23. As a result of glycosylation, DTT-reduced protein migrates as 90-110 kDa polypeptide in SDS-PAGE.

Endotoxin
Less than 1.0 EU per μg of the rhHER2 by the LAL method.

Purity
>95% as determined by SDS-PAGE

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4C-8C); After reconstitution under sterile conditions for 1 month (4C-8C) or 3 months (-20C to -70C).

Bioactivity
Measured by its binding ability in a functional ELISA.
Immobilized Human Her2, His Tag (Catalog # HE2-H5225) at 0.05 μg/mL (100 μL/well) can bind trastuzumab with a linear ranger of 0.05-3 ng/mL.

References

(1) Kanai, Y. et. al. (1995) Biochem. Biophys. Res. Commun.208:1067.
(2) Codony-Seeervat, J. et al., 1999, Cancer Res. 59: 1196-1201.
(3) Tzahar, E. et al., 1998, Biochim. Biophys. Acta. 1377: 25-37.
(4) Kermit, L. et al, 1999, J. Biol. Chem. 274: 5263-5266.
(5) Hellyer, N.J. et. al. (2001) J. Biol. Chem. 276:42153.
(6) Daly, R.J. (1999) Growth Factors 16:255.